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Genetic variants associated with lung function:
the long life family study
Bharat Thyagarajan1*, Mary Wojczynski2, Ryan L Minster3, Jason Sanders4, Sandra Barral5, Lene Christiansen6,
R Graham Barr7,8, CHARGE consortium, SpiroMeta consortium and Anne Newman4

Abstract
Background: Reduced forced expiratory volume in 1 second (FEV1) and the ratio of FEV1 to forced vital capacity
(FVC) are strong predictors of mortality and lung function is higher among individuals with exceptional longevity.
However, genetic factors associated with lung function in individuals with exceptional longevity have not been
identified.
Method: We conducted a genome wide association study (GWAS) to identify novel genetic variants associated
with lung function in the Long Life Family Study (LLFS) (n = 3,899). Replication was performed using data from the
CHARGE/SpiroMeta consortia. The association between SNPs and FEV1 and FEV1/FVC was analyzed using a linear
mixed effects model adjusted for age, age2, sex, height, field center, ancestry principal components and kinship
structure to adjust for family relationships separately for ever smokers and never smokers. In the linkage analysis, we
used the residuals of the FEV1 and FEV1/FVC, adjusted for age, sex, height, ancestry principal components (PCs),
smoking status, pack-years, and field center.
Results: We identified nine SNPs in strong linkage disequilibrium in the CYP2U1 gene to be associated with FEV1
and a novel SNP (rs889574) associated with FEV1/FVC, none of which were replicated in the CHARGE/SpiroMeta
consortia. Using linkage analysis, we identified a novel linkage peak in chromosome 2 at 219 cM for FEV1/FVC
(LOD: 3.29) and confirmed a previously reported linkage peak in chromosome 6 at 28 cM (LOD: 3.33) for FEV1.
Conclusion: Future studies need to identify the rare genetic variants underlying the linkage peak in chromosome 6
for FEV1.
Keywords: GWAS, Lung function, Aging

Introduction
Pulmonary function, as determined by spirometry, indicates the physiological state of the airways and lung. Pulmonary function measures such as forced expiratory
volume in one second (FEV1), forced vital capacity
(FVC) and the ratio of the two measures (FEV1/FVC)
are used to diagnose chronic obstructive pulmonary disease (COPD) and assist in the diagnosis of asthma,
which are major causes of death and morbidity worldwide [1]. Reduced (FEV1) and forced vital capacity
(FVC), in healthy asymptomatic adults, are predictors of
cardiovascular disease mortality and all cause mortality,
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independent of smoking history [2-9]. The Danish 1905
cohort study also showed that higher FEV1 and peak expiratory flow (PEF) in nonagenarians to be associated
with lower mortality [10]. Due to the strong and consistent association with mortality, pulmonary function has
been viewed as a biomarker of aging itself [11]. We have
previously shown that the prevalence of self-reported
COPD was 3 times lower in the Long Life Family Study
(LLFS) as compared to the other similarly aged cohorts
[12] suggesting that LLFS participants, who were selected for exceptional familial longevity, may have better
lung function as compared to the general population.
These findings are supported by a previous study that
reported male offspring of long lived parents had higher
lung function as compared to those with short lived parents [13]. Several studies have shown that pulmonary
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function measures are heritable characteristics with estimates ranging from 38% for FEV1 to 37% for FEV1/FVC
[14-16]. However, the 26 genetic loci associated with
FEV1/FVC, FEV1 or both (23 loci associated with FEV1/
FVC and 10 loci associated with FEV1) [17-19] in genome wide association studies explain only around 3%
of the variance in FEV1/FVC and around 1.5% of the
variance in FEV1 [18]. Furthermore, the mean age of
Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE)/SpiroMeta consortia was 55 years;
hence, it identified genes for lung function among older
adults. Since findings from the LLFS [12] and a previous
study [13] suggest that there may be genetic determinants of lung function among exceptionally long lived
individuals and families, we conducted a genome wide
association and linkage study among participants of the
LLFS, a family based cohort of exceptional longevity, to
identify novel genetic determinants of lung function in
this unique sample.

Material and methods
Cohort description and study design

The LLFS study design has also been described in detail
previously [12]. Briefly, the LLFS is a family-based cohort study (n = 4,559) that enrolled long-lived probands
and their siblings (n = 1,445), their offspring (n = 2,329)
and spousal controls (n = 785) recruited from 3 U.S. field
centers (Boston University Medical Center in Boston
MA, Columbia College of Physicians and Surgeons in
New York City NY, and the University of Pittsburgh in
Pittsburgh PA) and the University of Southern Denmark
to identify genetic determinants of longevity in these
families. At the U.S. field centers, an initial recruitment
brochure was mailed to all people in the Center for
Medicare and Medicaid Services list of Medicare enrollees who were ≥89 years old on January 1, 2005, were
not in end stage renal disease or hospice programs and
lived in zip codes within 3 hours driving distance of one
of the three U.S field centers. Mailings were conducted
in collaboration with CMS and the NIA via an IntraAgency Agreement. Study participants were also recruited
from the local communities using mailed brochures, posters, web-based media and newspaper advertisements as
well as community presentations at churches and senior
centers. Additional mailing lists were obtained through
local government agencies or purchased public domain
lists from commercial vendors. The University of Southern
Denmark used the Danish National Register of Persons to
identify individuals who were ≥90 years during the study
recruitment period without any restrictions on residence
[20]. Only families who had the proband, at least one living
sibling, and one of their living offspring (minimum family
size of 3) with a Family Longevity Selection Score (FLoSS)
of 7 or higher that correlates well with later-observed
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longevity [21] and gave informed consent and were willing
to participate in the interview and examination including
donating a blood sample were eligible to participate in this
study. This strategy led to the enrollment of families with
the greatest potential utility for phenotypic and genetic
studies of exceptional survival in families. All research was
performed in compliance with the Helsinki Declaration.
Written informed consent was obtained from all enrollees.
In a few cases of cognitive impairment, family members
were enrolled via proxy consent, provided that the participant was able to express assent at the time of the
examination. This study was approved by the Institutional
Review Boards at all the institutions in the United States
of America and Denmark.
After excluding 15% of the participants due to presence
of non-European ancestry (n = 6), low quality spirometry
(defined as 2 or more acceptable spirometry maneuvers
with reproducibility within 250 mL) (n = 295), selfreported pulmonary fibrosis (n = 11) obtained during an
in-person interview, history of lung volume reduction surgery (n = 14), or missing genotypes (n = 344), a total of
3,889 participants were included in the present analysis.
Lung function measurements

The examinations were conducted in the home setting
with portable equipment by centrally trained and certified research assistants using a standardized protocol.
Lung function was measured with a portable spirometer
(EasyOne Diagnostic, NDD Medical Technologies, Andover, MA) following American Thoracic Society guidelines [22]. Calibration checks and the best 3 maneuvers
were reviewed centrally by one investigator. Only spirometry tests with 2 or more acceptable maneuvers with
reproducibility within 250 mL were selected for further
data analyses.
Genotyping and imputation

The Human Omni chip 2.5 v1 (Illumina Inc., Ca), was used
to genotype all the LLFS participants at the Center for
Inherited Disease Research (CIDR). Ancestry principal
components (PCs), to control for population structure,
were produced with EIGENSTRAT [23] on 1,515 LLFS unrelated individuals using 120,093 tag SNPs, where in advance any SNPs with minor allele frequencies (MAF) <5%,
Hardy Weinberg Equilibrium (HWE) p <1E-06, and with
missing genotypes were excluded. Ancestry PCs produced
from unrelated subjects were expanded, within EIGENS
TRAT framework, to all members of LLFS. Genotype imputations were performed based on the cosmopolitan
phased haplotypes of 1000 Human Genome (1000HG, version 2010–11 data freeze, 2012-03-04 haplotypes) using
MACH and MINIMACH [24,25] and a total of 38,045,518
SNPs were imputed. When MAF ≥ 0.05 and r2 > 0.3 for imputed SNP filters were applied to the hybrid dataset for
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analysis, the number of SNPs for analysis is reduced to
6,522,421 (from a total of 38,245,546 SNPs), of which
1,204,935 SNPs were genotyped and 5,317,486 SNPs were
imputed.
Statistical analysis

The statistical models used to test the association between the GWAS SNPs and lung function (FEV1 and
FEV1/FVC) were identical to the models used by the
CHARGE/SpiroMeta consortia [18], except that the
LLFS study also included adjustment for kinship structure to facilitate replication of results in the CHARGE/
SpiroMeta consortia. We employed a linear mixed effects model which adjusted for age, age2, sex, height,
field center and ancestry PCs (PC1-20) in addition to
the kinship matrix. The adjusted phenotypic residuals
from these models (FEV1 and FEV1/FVC) were inverse
normal transformed to normally distributed z-scores.
These transformed residuals were then used as the phenotype for association testing under an additive genetic model,
separately for ever smokers and never smokers. The associations between individual SNPs the FEV1 (milliliters) and
FEV1/FVC (percent) were analyzed using a linear mixed
effects model with kinship structure [26,27] to adjust for
family relationships separately for ever smokers and never
smokers. The effect estimates and standard errors for eversmokers and never smokers were meta-analyzed using
inverse-variance weighting.
We used the same criteria as the CHARGE/SpiroMeta
consortia for assessing genetic associations [18]. All SNPs
that showed a borderline association (p < 5E-06) with FEV1
and FEV1/FVC in LLFS were evaluated for their association with FEV1 and FEV1/FVC in the CHARGE/SpiroMeta consortia [18] using statistical models identical to
those described above (individual family-based studies
within the CHARGE/SpiroMeta did adjust for kinship
structure while other studies within the consortia did not
adjust for kinship structure). Finally, genotypes from both
LLFS and CHARGE/SpiroMeta were meta-analyzed using
METAL to evaluate the overall association between individual SNPs and lung function in both studies. We also
evaluated the replication of previously reported GWAS hits
(from the CHARGE/SpiroMeta consortia) for FEV1 and
FEV1/FVC in the LLFS population using the statistical
models described above.
To calculate Identity by Descent (IBD) for the linkage
analyses, the ZAPLO program was used to estimate haplotypes of SNPs in small regions (0.5 cM intervals) [28].
The deCODE map was used to approximate the cM positions [29]. We identified all SNPs in our GWAS scan
with no Mendel inconsistencies and an average pedigree
heterozygosity ≥0.1. Within each 0.5 cM interval we
used the first five such SNPs to construct a haplotype
and if there were fewer than 5, we took all such SNPs in
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the interval. With the resulting haplotypes, IBD at 1 cM
intervals was estimated in the Loki program [30], which
does chromosome-wide IBD estimation in intact pedigrees. These IBD estimates were then used in the SOLAR
package [31] to conduct a variance-component linkage
analysis. In the linkage analysis, we used the residuals of
the FEV1 and FEV1/FVC phenotypes, adjusted for age,
sex, height, ancestry PCs, smoking status (current, former,
never), pack-years, and field center. The SOLAR package
was also used to estimate heritability and empirical p of
LOD.

Results
There were 1,734 (45%) male participants and 2155 (55%)
female participants with an average age of 68.6 years
(standard deviation: 15.2 years) and an average BMI of
27.13 kg/m2 (standard deviation: 4.79 Kg/m2). There were
2,203 (57%) never smokers, 1,403 (40%) former smokers
and 283 (3%) current smokers. The average number of
cigarettes smoked among former smokers was 20.26 pack
years (standard deviation: 22.07 pack years) while the average number of cigarettes smoked among current smokers
was 28.25 pack years (standard deviation:19.03 pack
years). There were 89 participants (2.3%) with selfreported history of chronic obstructive pulmonary disease
(COPD) and 339 (8.7%) participants with self-reported
history of asthma, 123 (3.1%) participants with a selfreported history of congestive heart failure and 11 (0.28%)
participants with a self reported history of lung cancer. As
shown in Table 1, the LLFS population was significantly
older (68.6 ± 15.2 years vs. 53.5 ± 7.7 years; p < 0.0001) and
had significantly higher percent never-smokers (57% vs.
42%; p < 0.0001) as compared to CHARGE/SpiroMeta
consortia. In addition, LLFS had slightly lower FEV1
(2455 ml vs. 2963; p < 0.0001) and FEV1/FVC (0.76 vs.
0.78; p < 0.0001) as compared to the CHARGE/SpiroMeta
consortia (Table 1).
We evaluated 6,522,421 SNPs across 3,889 individuals.
The Q-Q plots for FEV1 and FEV1/FVC are shown in
Additional file 1: Figures S1a and S1b respectively, while
the Manhanttan plots for FEV1 and FEV1/FVC are
shown in Additional file 1: Figures S2a and S2b respectively. Overall, we found 130 SNPs (23 genotyped SNPs
and 107 imputed SNPs) that showed borderline association with FEV1 (p < 5E-06) (Additional file 2: Table S1)
and 74 SNPs (14 genotyped SNPs and 60 imputed SNPs)
that showed borderline association with FEV1/FVC
(p < 5E-06) (Additional file 2: Table S2). There was one
SNP, rs71374110 in the ANKRD11 gene that showed a
borderline association with both FEV1 and FEV1/FVC
(Additional file 2: Tables S1 and S2). Among the GWAS
SNPs with borderline association, 49 SNPs for FEV1 and
28 SNPs for FEV1/FVC were available for replication in
the CHARGE/SpiroMeta dataset (Additional file 2: Tables
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Table 1 Comparison of demographic and lung function variables* in LLFS and CHARGE/SpiroMeta consortia+
LLFS (n = 3889)

CHARGE/SpiroMeta (n = 48201)

p value

Age (years)

68.6 (15.2)

53.5 (7.7)

<0.0001

Sex (% Male)

44

44

0.62

Smoking Status (% never smoker)

56.6

42.0

<0.0001

FEV1 (ml)

2455 (866)

2963 (798)

<0.0001

FEV1/FVC

0.76 (0.07)

0.78 (0.09)

<0.0001

*

Values are means (standard deviations in parentheses) or percentages.
Values for the demographic and lung function variables in the CHARGE/SpiroMeta consortia were calculated using previously published data (Additional file 2:
Table S1 a in Soler Artigas et al.) [18].
+

S3 and S4 respectively). The results for the GWAS SNPs
with p <9.0E-07 are presented in Tables 2 and 3 and the
data for all SNPs are presented in Additional file 2: Tables
S1 and S2. As shown in Table 2, rs1493131 in the CYP2U1
gene showed borderline association with FEV1 (p = 7.4E07). In addition, 7 imputed SNPs in the CYP2U1 gene and
1 imputed SNP in the PHACTR2 gene also showed a borderline association with FEV1 (p < 9.2E-07). However, none
of these SNPs were associated with FEV1 in the CHARGE/
SpiroMeta consortia or in the overall meta-analysis. Five of
the 9 previously identified GWAS SNPs (p < 1E-07) for
FEV1 were nominally associated with FEV1 in LLFS
(p < 0.05) (Additional file 2: Table S5). For FEV1/FVC, one
SNP, rs889574 in the ANKRD11 gene, demonstrated a borderline association (p = 1.6E-07) in the LLFS GWAS,
(Table 3). Seven of 22 previously identified GWAS SNPs
(p < 1E-07) were also associated with FEV1/FVC in the
LLFS (p < 0.05) (Additional file 2: Table S6). A complete list
of all SNPs associated with lung function (p < 5E-06) is
shown in Additional file 2: Tables S1 and S2, with their annotation and quality control information.
The heritability of FEV1 and FEV1/FVC as estimated by
the SOLAR package was 0.37 ± 0.043 and 0.34 ± 0.040 respectively in the LLFS. The highest LOD score obtained
for FEV1 was 3.33 localized to 28 cM (chr 6: 9275152 bp –
9467267 bp) at the q terminus of chromosome 6 (Figure 1).
This locus remained significant (LOD = 3.18) even after adjustment for 3 GWAS SNPs/indels located between
26 cM-34 cM on chromosome 6 and were nominally associated with FEV1 (p < 0.001) (Additional file 2: Table S7). A
more comprehensive adjustment for 19 GWAS SNPs that
were nominally associated with FEV1 (p < 1E-03) over a
larger range (10 cM – 50 cM) further attenuated the linkage peak (LOD = 2.60) but did not completely explain the
linkage peak (Additional file 2: Table S7). The highest
LOD score obtained for FEV1/FVC was 3.29 localized
to 219 cM in chromosome 2 (chr 2: 217963480 bp –
218313210 bp) (Figure 2). This locus did not remain significant (LOD =2.2) after adjustment for 10 GWAS SNPs
located between 217 cM −236 cM nominally associated
with FEV1/FVC (p < 0.001) (Additional file 2: Table S7)
and was almost completely explained (LOD: 1.01) by adjustment of GWAS SNPs (n = 38) in a broad region from

200–250 cM that were associated with FEV1/FVC (p <
0.001) (Additional file 2: Table S7). Further adjustment
for additional covariates such as age2, height2, BMI, for
self-reported COPD/asthma and those who took asthma/
COPD/bronchitis medications did not significantly change
results of the linkage analyses Additional file 1: Figures
S3a and S3b.

Discussion
This study identified a novel linkage peak in chromosome 2 for FEV1/FVC and confirmed a previously identified linkage peak in chromosome 6 for FEV1. This
study also replicated some of the GWAS SNPs identified
in previous studies. Though this study identified SNPs in
the CYP2U1 and PHACTR2 genes that were associated
with FEV1, these findings could not be replicated in independent datasets.
Two previous reports identified a linkage peak for FEV1
at the same locus (chromosome 6 at 28 cM (~280 kb)) as
the present study [32,33]. As compared to previous linkage studies we had improved marker density (average
marker spacing = 0.5 cM) and improved accuracy by using
haplotype-based IBD estimation. The availability of
GWAS data also allowed us to evaluate whether GWAS
SNPs under the linkage peak explained the linkage peak
identified for FEV1. While we found a modest attenuation
of the FEV1 linkage peak after adjustment for common
GWAS SNPs under the linkage peak that were nominally
associated with FEV1 (p < 0.001), they did not completely
explain the linkage peak. In contrast, the novel linkage
peak identified in chromosome 2 at 219 cM (~372 kb) for
FEV1/FVC was almost completely explained, by adjustment for the common GWAS SNPs under the linkage
peak that were nominally associated with FEV1/FVC
(p < 0.001). These findings suggest that common variants
alone are insufficient to explain some linkage peaks such
as the linkage peak in chromosome 6 for FEV1. As shown
in other diseases, the inability to identify association under
linkage peaks could in part be attributable to the fact that
only common variants are examined under the linkage
peak whereas the linkage signal could be caused by multiple rare variants with higher penetrance [34]. Hence, the
contribution of multiple rare variants with high penetrance

LLFS

CHARGE/SPIROMETA CONSORTIA

META ANALYSIS

Coded allele
frequency

β (SE)

P_value Coded allele
frequency

β (SE)

P_value Coded allele
frequency

β (SE)

P_value HetPVal N

PHACTR2 C/G

0.33

−0.121
(0.025)

8.83E-07 0.33

0.002
(0.008)

0.78

0.33

−0.008
(0.007)

0.25

1.80E-06 51073

CYP2U1

C/G

0.23

0.139
(0.028)

8.24E-07 0.22

−0.005
(0.009)

0.53

0.22

0.007
(0.008)

0.42

9.48E-07 51687

rs4956031* Chr4: 108857140

CYP2U1

T/C

0.23

0.138
(0.028)

9.17E-07 0.22

−0.005
(0.009)

0.52

0.22

0.007
(0.008)

0.43

1.04E-06 51715

rs998405

Chr4: 108862837

CYP2U1

C/G

0.23

0.139
(0.028)

7.93E-07 0.22

−0.006
(0.009)

0.50

0.22

0.006
(0.008)

0.43

8.18E-07 51501

rs17564501 Chr4: 108863209

CYP2U1

A/C

0.77

−0.139
(0.028)

7.93E-07 0.78

0.006
(0.009)

0.50

0.78

−0.006
(0.008)

0.44

8.15E-07 51456

rs1493122

Chr4: 108864651

CYP2U1

T/C

0.77

−0.139
(0.028)

7.59E-07 0.79

0.006
(0.009)

0.47

0.78

−0.006
(0.008)

0.46

7.40E-07 51105

rs1493131* Chr4: 108860906

CYP2U1

A/G

0.23

0.139
(0.028)

7.37E-07 0.22

−0.006
(0.009)

0.47

0.22

0.006
(0.008)

0.46

7.23E-07 51877

rs11724895 Chr4: 108865791

CYP2U1

C/G

0.77

−0.139
(0.028)

7.72E-07 0.79

0.006
(0.009)

0.46

0.78

−0.006
(0.008)

0.47

8.06E-07 51068

rs17564543 Chr4: 108863481

CYP2U1

T/C

0.77

−0.138
(0.028)

9.07E-07 0.78

0.007
(0.009)

0.40

0.78

−0.005
(0.008)

0.53

7.47E-07 50935

SNP

Chromosomal
position

Gene

rs9390140

Chr 6: 144127026

rs1493126

Chr 4:108855828

Coded/noncoded allele
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Table 2 GWAS findings for FEV1 in the LLFS (p <1E-07) and replication in the CHARGE/SpiroMeta consortia

*These SNPs were genotyped using the Human Omni chip 2.5 v1 (Illumina Inc., Ca). Other SNPs were imputed.
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Table 3 GWAS findings for FEV1/FVC in the LLFS (p <1E-07) and replication in the CHARGE/SpiroMeta consortia
LLFS
SNP

Chromosomal
position

rs889574* Chr16: 89386808

Gene

Coded/noncoded allele

ANKRD11 T/C

CHARGE/SPIROMETA CONSORTIA

META ANALYSIS

Coded allele
frequency

β (SE)

P_value Coded allele
frequency

β (SE)

P_value Coded allele
frequency

β (SE)

P_value HetPVal N

0.31

0.129
(0.025)

1.63E-07 0.34

0.003
(0.007)

0.67

−0.013
(0.007)

0.06

0.66

9.99E-07 50425

*These SNPs were genotyped using the Human Omni chip 2.5 v1 (Illumina Inc., Ca). Other SNPs were imputed.
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Figure 1 Linkage peaks on chromosome 6 associated with FEV1 before and after adjustment for GWAS SNPs under the linkage peak
associated with FEV1. Original linkage is in red, the linkage in blue is for adjustment of GWAS SNPs (n = 3) in a narrow region from 26–34 cM
that were associated with p < 1E-03, and green is the linkage after adjustment of GWAS SNPs (n = 19) in a broad region from 10–50 cM that were
associated with p < 1E-03.

under the linkage peak towards FEV1 needs to be evaluated
in future studies. The linkage peak identified in chromosome 6 at 28 cM (~280 kb) for FEV1 does not contain any
known genes. However, there are several DNase I hypersensitivity sites and putative transcription factor binding
sites (9H3K27Ac marks) that have been identified in cells
from pulmonary epithelium and blood vessels derived from
the pulmonary artery within this linkage peak (EnCode
data) suggesting that regulatory elements in this region
may play an important role in determining lung function.
The linkage peak for FEV1/FVC in chromosome 2 at
219 cM (~373 kb) contains the genomic region that codes
for the DIRC3 gene, a non coding RNA that is involved in

the pathogenesis of familial renal cancers (EnCode data).
Though DIRC3 is expressed in pulmonary tissue its role
in determining lung function has not been evaluated. Furthermore, this region also contains DNase I hypersensitivity sites or putative transcription factor binding sites
(9H3K27Ac marks) in cells derived from the pulmonary
epithelium or vasculature. Thus the linkage peaks identified in this study on chromosomes 2 and 6 may indicate
previously unidentified regulatory pathways that may influence longevity through their effect on lung function.
Though this study identified a few novel GWAS SNPs
that were associated with FEV1 and FEV1/FVC, none of
these findings could be replicated in the CHARGE/Spiro

Figure 2 Linkage peaks on chromosome 2 associated with FEV1/FVC before and after adjustment for GWAS SNPs under the linkage
peak associated with FEV1/FVC. Original linkage is in red, the linkage in blue is for adjustment of GWAS SNPs (n = 10) in a narrow region from
217–236 cM that were associated with p < 1E-03, and green is the linkage after adjustment of GWAS SNPs (n = 38) in a broad region from
200–250 cM that were associated with p < 1E-03.
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Meta consortia. However, only 38% of SNPs associated
with FEV1 or FEV1/FVC in LLFS were available for replication in the CHARGE/SpiroMeta consortia. Thus, the
remaining SNPs and insertion/deletions polymorphisms
associated with FEV1 and FEV1/FVC in LLFS but not genotyped/imputed in the CHARGE/SpiroMeta consortia
will need to be evaluated in future studies. Since the LLFS
study participants were not randomly selected to represent the general population but were specifically selected
for their family history of exceptional longevity, it is possible that there may be some unique genotypes associated
with lung function that may not be replicated in studies
that are more representative of the general population.
One previous study showed that elderly male offspring
(range: 65–89 years) with long lived parents (age at death
of at least on parent >80 years) had FEV1 that was 330 ml
larger than FEV1 for male offspring with short lived parents even after controlling for smoking [13]. The findings
of the present study along with previous findings [13]
might indicate that long lived families have unique genetic
variants that contribute to higher lung function among
those with exceptional longevity. This study also replicated 12 of 31 GWAS hits for FEV1 and FEV1/FVC identified in previous meta-analysis (Additional file 2: Tables S5
and S6). The reasons for not confirming all previously
identified variants in this study may include limited power,
population specific genetic heterogeneity and differences
in environmental exposures such as smoking. Genetic heterogeneity in contribution towards determination of lung
function in elderly participants (average age among LLFS
participants: 68.8 years) as compared to middle aged
adults may also contribute to the differences in genetic association observed in the LLFS study as compared to previous studies. As shown in Additional file 2: Tables S3 and
S4, several SNPs had highly significant p for heterogeneity
between the LLFS and the CHARGE/SpiroMeta dataset
supporting the idea that, at least for some loci, heterogeneity in genetic contribution may account for the lack of
replication of certain loci.

Conclusion
The family-based cohort design of the LLFS with extensive genotype information and detailed lung function measurements makes this study a valuable resource to identify
genetic determinants of lung function. In addition to confirming some of the previously identified GWAS SNPs
and a previously identified linkage peak in chromosome 6
for FEV1, this study also identified a novel linkage peak in
chromosome 2 for FEV1/FVC. Repeated measurements of
lung function in this study population along with targeted
resequencing under the observed linkage peaks in future
studies may help clarify the role of genetic variants in determining preserved lung function among exceptionally
long lived individuals.
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Additional files
Additional file 1: Supplementary Figures for lung function-RespR.
Figure S1a; Figure S1b; Figures S2a; Figure S2b; Figure S3a; Figure S3b.
Quality control for genotyped SNPs; Q-Q plot showing distribution of
observed p values for FEV1; Q-Q plot showing distribution of observed
p values for FEV1/FVC; Manhattan plots of GWAS results for FEV1;
Manhattan plots of GWAS results for FEV1/FVC; Linkage peaks on
chromosome 6 associated with FEV1; Linkage peaks on chromosome 2
associated with FEV1/FVC.
Additional file 2: Table S1. FEV1 GWAS results with suggestive association
(p-value<5E-06) from LLFS, regardless of replication or look-up. Table S2.
FEV1/FVC GWAS results with suggestive association (p-value<5E-06) from
LLFS, regardless of replication or look-up. Table S3. FEV1 GWAS results from
LLFS with look-up in CHARGE/SPIROMETA consortia and meta-analysis of
LLFS and CHARGE/SPIROMETA. Table S4. FEV1/FVC GWAS results from LLFS
with look-up in CHARGE/SPIROMETA consortia and meta-analysis of LLFS and
CHARGE/SPIROMETA. Table S5. Examination of published association SNPs
for FEV1 in LLFS FEV1 GWAS. Table S6. Examination of published association
SNPs for FEV1/FVC in LLFS FEV1 GWAS. Table S7. Three GWAS SNPs located
between 26 cM-34 cM within the linkage peak in chromosome 6 for FEV1;
Nineteen GWAS SNPs located between 10 cM-50 cM within the linkage peak
in chromosome 6 for FEV1; Ten GWAS SNPs located between 217 cM-236 cM
within the linkage peak in chromosome 2 for FEV1/FVC; Thirty eight GWAS
SNPs located between 200 cM-250 cM within the linkage peak in
chromosome 2 for FEV1/FVC.
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